Enliven Therapeutics, Inc.
NASDAQ:ELVNBiotechnology
-$0.12 today
- Market cap
- $3.30B
- Beta
- 0.40
- P/E (TTM)
- -28.4
- EPS (TTM)
- -$1.57
Volume 0.75M
Average 1.35M
ELVN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Enliven Therapeutics, Inc.NASDAQ: ELVN
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $28.02M rose 53.8% year over year, ahead of the +16.0% change in trailing-twelve-month research & development. Sequentially, it fell 3.4% from the prior quarter. Over 3 fiscal years it compounded at +40.4% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +53.8% holds above the trailing-twelve-month pace of +16.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 85.86M USD
- Year-over-year change
- +6.3%
- 4-year CAGR
- +43.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 85.86M | +6.3% |
| FY2024 | 2024-12-31 | 80.78M | +25.1% |
| FY2023 | 2023-12-31 | 64.57M | +108.2% |
| FY2022 | 2022-12-31 | 31.02M | +51.5% |
| FY2021 | 2021-12-31 | 20.47M | — |
Research & Development vs competitors
How ELVN compares with its peers on the latest reported figures
- ELVN's LTM Sep 2026 research & development of $98.95M is the lowest of the 11 companies compared; the peer median is $222.03M.
- Its year-over-year change of +16.0% is the 5th highest of 11, against a peer median of +7.1%.
- Over three fiscal years its annual growth of +40.4% compares with a peer median of +24.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.15B | +9.1% | +8.9% | 37.0% | |
| LTM Jun 2026 | $1.29B | +68.1% | +57.0% | — | |
| LTM Jul 2026 | $824.32M | -6.8% | -2.6% | 33.8% | |
| LTM Jun 2026 | $270.72M | -4.1% | +2.0% | 2615.7% | |
| LTM Mar 2026 | $255.99M | +3.7% | +29.7% | 117.9% | |
| LTM Mar 2026 | $188.07M | +22.3% | +26.8% | — | |
| LTM Mar 2026 | $129.68M | +5.2% | +71.4% | — | |
| LTM Jun 2026 | $128.85M | +18.2% | +9.4% | 75.8% | |
| LTM Mar 2026 | $116.62M | -0.1% | +21.2% | — | |
| LTM Mar 2026 | $111.3M | +26.9% | +33.8% | — | |
| LTM Sep 2026 | $98.95M | +16.0% | +40.4% | — | |
| Peer median (excluding ELVN) | $222.03M | +7.1% | +24.0% | 75.8% | |
Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 263K |
| Gross Profit | 0 | 0 | 0 | 0 | (263K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 20.47M | 31.02M | 64.57M | 80.78M | 85.86M |
| Selling, General & Admin | 4.29M | 7.77M | 18.96M | 23.78M | 33.8M |
| Operating Expenses | 24.76M | 38.79M | 83.53M | 104.55M | 119.4M |
| Depreciation & Amortization | 115K | 215K | 297K | 317K | 263K |
| EBITDA | (24.63M) | (37.45M) | (71.29M) | (88.48M) | (103.43M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (24.76M) | (38.79M) | (83.53M) | (104.55M) | (119.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 22K | 1.13M | 11.97M | 14.89M | 16.01M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 22K | 1.13M | 11.95M | 15.76M | 15.96M |
| Income Before Tax | (24.74M) | (37.66M) | (71.58M) | (88.79M) | (103.69M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 232K | 0 |
| Net Income | (24.74M) | (37.66M) | (71.58M) | (89.02M) | (103.69M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.17) | (6.03) | (2.01) | (1.89) | (1.83) |
| EPS (Diluted) | (3.17) | (6.03) | (2.01) | (1.89) | (1.83) |
| Weighted Avg Shares | 7.81M | 6.25M | 35.55M | 47.07M | 56.66M |
| Weighted Avg Shares (Diluted) | 7.82M | 6.25M | 35.55M | 47.07M | 56.66M |
Enliven Therapeutics, Inc.
NASDAQ:ELVN
Intrinsic Alpha fair value
Locked
Current Price
$44.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.